Mon panier

Fluorescent Human Claudin-6 / CLDN6 Full Length Protein (VLP)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
CL6-HF2G8-20ug
$620.00
CL6-HF2G8-100ug
$1235.00
CL6-HF2G8-500ug (250ug X 2)
$4305.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Application

    1. Immunization
    2. Cell based assay (FACS or functional assay)
    3. Screening (ELISA)
  • Synonyms

    Claudin-6, CLDN6

  • Source

    Fluorescent Human Claudin-6 Full Length Protein (VLP) (CL6-HF2G8) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Val 220 (Accession # P56747).

    Predicted N-terminus: Asp

  • Molecular Characterization

    This protein carries a GFP tag.

    *The isotype control of empty/mock VLP (Cat. No. VLP-NF2P4) is sold separately and not included in protein, you can follow the link for product information.

    1. Structure

      Virus-like particles (VLPs) are protein particles that mimic the shape of viruses but lack a viral genome, and incorporating transmembrane proteins on the external surface.

    2. Synthesis Process

      Envelope virus-like particles (eVLPs) are produced by co-expressing target membrane proteins with viral structural proteins in mammalian cells, enabling native embedding of membrane proteins into the lipid bilayer during VLP budding. This approach preserves authentic conformation, post-translational modifications, and orientation, while creating a completely detergent-free environment with repetitive multivalent display and strong immunogenicity making them ideal for immunization, binding assays in antibody discovery and screening (ELISA), and cell-based assays such as FACS, etc.

  • Conjugate

    GFP

    Excitation source: 488 nm spectral line, argon-ion laser

    Excitation Wavelength: 488 nm

    Emission Wavelength: 530 nm

  • Purity

    >95% as determined by SEC-HPLC.

  • Formulation

    The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).

    Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Shipping and Storage

    This product is supplied and shipped on dry ice.

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 12 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SEC-HPLC

    Claudin-6 SEC-HPLC

    The purity of Fluorescent Human Claudin-6 Full Length Protein (VLP) (Cat. No. CL6-HF2G8) was greater than 95% as determined by SEC-HPLC.

  • Bioactivity-ELISA

     Claudin-6 ELISA

    Immobilized Fluorescent Human Claudin-6 Full Length Protein (VLP) (Cat. No. CL6-HF2G8) at 5 μg/mL (100 μL/well) can bind Monoclonal​ Anti-Human Claudin-6 antibody ,Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).

    Protocol
  • Bioactivity-SPR

     Claudin-6 SPR

    Fluorescent Human Claudin-6 Full Length Protein (VLP) (Cat. No. CL6-HF2G8) captured on L1 Chip can bind Anti-Claudin-6 Antibody, Human IgG1 with an affinity constant of 68.7 pM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  • Bioactivity-FACS

     Claudin-6 FACS

    2e5 of Anti-Claudin-6 CAR-293 cells were stained with 100 μL of 3 μg/mL of Fluorescent Human Claudin-6 Full Length Protein (VLP) (Cat. No. CL6-HF2G8) and negative control protein respectively. GFP signal was used to evaluate the binding activity (QC tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

An oncofetal tight junction protein absent in normal adult tissues but aberrantly expressed in ovarian, endometrial, and testicular cancers. Its strict cancer specificity and extracellular accessibility make it an ideal candidate for CAR-T cell therapy and bispecific antibody development.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Claudin 6

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    15 Détails

  • Étape de développement la plus élevée:

    Phase 2 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte